Pulmonology Advisor1d
TNKase Approved for Treatment of Acute Ischemic Stroke
The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.
The Cardiology Advisor2d
Survival Without Disability Not Improved With Intra-Arterial Urokinase in Stroke
Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.
MyChesCo on MSN2d
FDA Approves Lifesaving Stroke Drug, Xarelto Generics, and Issues Urgent Testosterone Warnings
The U.S. Food and Drug Administration (FDA) has released several important updates addressing new medication approvals and ...
EMS15d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Health and Me on MSN5d
FDA Approves TNKase To Treat Ischemic Strokes In Adults
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...
FDA Approves TNKase for Acute Ischemic Stroke
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
The Cardiology Advisor6d
ASA: Intra-Arterial Tenecteplase Beneficial for Large Vessel Occlusion
For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified ...